Mackenzie Financial Corp Sangamo Therapeutics, Inc Transaction History

Mackenzie Financial Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.42 - $1.38 $12,549 - $41,233	-29,879 Reduced 40.49%	43,920 $29,000
Q4 2023 Jan 30, 2024	BUY	$0.3 - $0.63 $9,300 - $19,531	31,003 Added 72.44%	73,799 $39,000
Q3 2023 Oct 25, 2023	BUY	$0.58 - $1.47 $7,092 - $17,975	12,228 Added 40.0%	42,796 $25,000
Q2 2023 Aug 03, 2023	BUY	$1.11 - $1.74 $33,930 - $53,188	30,568 New	30,568 $39,000
Q3 2022 Oct 07, 2022	BUY	$4.27 - $6.39 $387,024 - $579,176	90,638 New	90,638 $444,000
Q1 2021 May 14, 2021	SELL	$10.88 - $17.05 $195,840 - $306,900	-18,000 Closed	0 $0
Q4 2020 Feb 10, 2021	SELL	$9.23 - $18.18 $604,565 - $1.19 Million	-65,500 Reduced 78.44%	18,000 $281,000
Q3 2020 Nov 13, 2020	BUY	$9.38 - $12.48 $783,230 - $1.04 Million	83,500 New	83,500 $789,000

118

43.8M

576K

1.17M

Ticker SGMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 156,552,992
Market Cap $183M
Description
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.